An Additional Dose of Viral Vector COVID-19 Vaccine and mRNA COVID-19 Vaccine in Kidney Transplant Recipients: A Randomized Controlled Trial
Phase 3
Completed
- Conditions
- Adult KT recipientsimmunosuppression immunogenicity safety COVID-19
- Registration Number
- TCTR20211102003
- Lead Sponsor
- ational Research Council of Thailand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
All adult kidney transplant recipients who were fully vaccinated with SARS-CoV-2 vaccine however with inadequate immune response
Exclusion Criteria
Declined to participate
Allergic to vaccine given
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immunogenicity Week 0 and week 2 Check Humoral and cell-mediated immunity prior to additional dose of vaccine and 2 weeks after
- Secondary Outcome Measures
Name Time Method Safety Day 3 and day 7 Solicited and unsolicited adverse events at day 3 and day 7 after additional dose of vaccine